{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:23:38Z","timestamp":1787747018943,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SynAct Pharma ApS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The melanocortin 1 receptor (\n                    <jats:italic>MC1R<\/jats:italic>\n                    ) is a pro-resolving anti-inflammatory target under clinical development for scleroderma, arthritis, light intolerance or melanoma prevention. Genetic diversity at\n                    <jats:italic>MC1R<\/jats:italic>\n                    is high in certain populations, with some variants associated with loss-of function (LoF) resulting in red hair and poor tanning response. However, how these variants influence the anti-inflammatory efficacy of drug candidates targeting\n                    <jats:italic>MC1R<\/jats:italic>\n                    is unknown. We analysed the impact of 30 variants on receptor signalling (cAMP and phospho-ERK) and the anti-inflammatory response to nine agonists on the whole-blood assay on healthy volunteers. LoF presents as a continuum rather than as a binary characteristic (benign\/pathogenic) and differentially affects each signalling pathway, undermining the usefulness of in silico tools to predict variants pathogenicity. Moreover, variants affected compounds differently, even causing LoF, no effect or gain-of-function depending on the compound tested. We identified responders and non-responders to melanocortin compounds, and the efficacy of most compounds (determined as reduction of cytokine release) was diminished by the presence of variants at\n                    <jats:italic>MC1R<\/jats:italic>\n                    . Carrying red-hair variants (RHC) also associated with reduced efficacy but not having light skin phototype. These data encourage the incorporation of pharmacogenetics strategies during melanocortin drug development programs to ensure targeted interventions for maximal efficacy and safety.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-57399-0","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:14:38Z","timestamp":1781205278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The anti-inflammatory efficacy of melanocortin drugs is influenced by genetic variation at MC1R"],"prefix":"10.1038","volume":"16","author":[{"given":"Natalya","family":"Khodeneva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla S. A.","family":"Davan-Wetton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E. N.","family":"Jonassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Perretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinidad","family":"Montero-Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"57399_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00129785-200505010-00005","volume":"5","author":"MA Penny","year":"2005","unstructured":"Penny, M. A. & McHale, D. Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am. J. Pharmacogenom. 5, 53\u201362. https:\/\/doi.org\/10.2165\/00129785-200505010-00005 (2005).","journal-title":"Am. J. Pharmacogenomics"},{"key":"57399_CR2","doi-asserted-by":"publisher","unstructured":"Hauser, A. S. et al. Pharmacogenomics of GPCR drug targets. Cell 172, 41\u201354 e19 https:\/\/doi.org\/10.1016\/j.cell.2017.11.033 (2018).","DOI":"10.1016\/j.cell.2017.11.033"},{"key":"57399_CR3","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489. https:\/\/doi.org\/10.1371\/journal.pgen.1008489 (2019).","journal-title":"PLoS Genet."},{"key":"57399_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860. https:\/\/doi.org\/10.1038\/ng.3314 (2015).","journal-title":"Nat. Genet."},{"key":"57399_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","volume":"21","author":"D Ochoa","year":"2022","unstructured":"Ochoa, D. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat. Rev. Drug Discov. 21, 551. https:\/\/doi.org\/10.1038\/d41573-022-00120-3 (2022).","journal-title":"Nat. Rev. Drug Discov"},{"key":"57399_CR6","doi-asserted-by":"publisher","first-page":"101603","DOI":"10.1016\/j.smim.2022.101603","volume":"59","author":"T Montero-Melendez","year":"2022","unstructured":"Montero-Melendez, T., Boesen, T. & Jonassen, T. E. N. Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics. Semin Immunol. 59, 101603. https:\/\/doi.org\/10.1016\/j.smim.2022.101603 (2022).","journal-title":"Semin Immunol."},{"key":"57399_CR7","doi-asserted-by":"publisher","first-page":"1084394","DOI":"10.3389\/fimmu.2022.1084394","volume":"13","author":"N Khodeneva","year":"2022","unstructured":"Khodeneva, N., Sugimoto, M. A., Davan-Wetton, C. S. A. & Montero-Melendez, T. Melanocortin therapies to resolve fibroblast-mediated diseases. Front. Immunol. 13, 1084394. https:\/\/doi.org\/10.3389\/fimmu.2022.1084394 (2022).","journal-title":"Front. Immunol."},{"key":"57399_CR8","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1002\/humu.20788","volume":"29","author":"KA Beaumont","year":"2008","unstructured":"Beaumont, K. A., Shekar, S. N., Cook, A. L., Duffy, D. L. & Sturm, R. A. Red hair is the null phenotype of MC1R. Hum. Mutat. 29, E88\u201394. https:\/\/doi.org\/10.1002\/humu.20788 (2008).","journal-title":"Hum. Mutat."},{"key":"57399_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0092-8674(93)90572-8","volume":"72","author":"LS Robbins","year":"1993","unstructured":"Robbins, L. S. et al. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72, 827\u2013834. https:\/\/doi.org\/10.1016\/0092-8674(93)90572-8 (1993).","journal-title":"Cell"},{"key":"57399_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ng1195-328","volume":"11","author":"P Valverde","year":"1995","unstructured":"Valverde, P., Healy, E., Jackson, I., Rees, J. L. & Thody, A. J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat. Genet. 11, 328\u2013330. https:\/\/doi.org\/10.1038\/ng1195-328 (1995).","journal-title":"Nat. Genet."},{"key":"57399_CR11","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ng.2007.13","volume":"39","author":"P Sulem","year":"2007","unstructured":"Sulem, P. et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat. Genet. 39, 1443\u20131452. https:\/\/doi.org\/10.1038\/ng.2007.13 (2007).","journal-title":"Nat. Genet."},{"key":"57399_CR12","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-018-07691-z","volume":"9","author":"MD Morgan","year":"2018","unstructured":"Morgan, M. D. et al. Genome-wide study of hair colour in UK Biobank explains most of the SNP heritability. Nat. Commun. 9, 5271. https:\/\/doi.org\/10.1038\/s41467-018-07691-z (2018).","journal-title":"Nat. Commun."},{"key":"57399_CR13","first-page":"87","volume":"3","author":"S Safari","year":"2015","unstructured":"Safari, S., Baratloo, A., Elfil, M. & Negida, A. Evidence based emergency medicine part 2: Positive and negative predictive values of diagnostic tests. Emerg. (Tehran). 3, 87\u201388 (2015).","journal-title":"Emerg. (Tehran)"},{"key":"57399_CR14","doi-asserted-by":"publisher","unstructured":"Lotta, L. A. et al. Human gain-of-function MC4R variants show signaling bias and protect against obesity. Cell 177, 597\u2013607 e599  https:\/\/doi.org\/10.1016\/j.cell.2019.03.044 (2019).","DOI":"10.1016\/j.cell.2019.03.044"},{"key":"57399_CR15","doi-asserted-by":"publisher","first-page":"eadg7492","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492. https:\/\/doi.org\/10.1126\/science.adg7492 (2023).","journal-title":"Science"},{"key":"57399_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/s41422-021-00557-y","volume":"31","author":"S Ma","year":"2021","unstructured":"Ma, S. et al. Structural mechanism of calcium-mediated hormone recognition and Gbeta interaction by the human melanocortin-1 receptor. Cell. Res. 31, 1061\u20131071. https:\/\/doi.org\/10.1038\/s41422-021-00557-y (2021).","journal-title":"Cell. Res."},{"key":"57399_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1210\/me.2010-0217","volume":"25","author":"C Herraiz","year":"2011","unstructured":"Herraiz, C. et al. Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol. Endocrinol. 25, 138\u2013156. https:\/\/doi.org\/10.1210\/me.2010-0217 (2011).","journal-title":"Mol. Endocrinol."},{"key":"57399_CR18","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1242\/jcs.128322","volume":"126","author":"M Abrisqueta","year":"2013","unstructured":"Abrisqueta, M. et al. Differential and competitive regulation of human melanocortin 1 receptor signaling by beta-arrestin isoforms. J. Cell. Sci. 126, 3724\u20133737. https:\/\/doi.org\/10.1242\/jcs.128322 (2013).","journal-title":"J. Cell. Sci."},{"key":"57399_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/pcmr.12257","volume":"27","author":"JC Garcia-Borron","year":"2014","unstructured":"Garcia-Borron, J. C., Abdel-Malek, Z. & Jimenez-Cervantes, C. MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell. Melanoma Res. 27, 699\u2013720. https:\/\/doi.org\/10.1111\/pcmr.12257 (2014).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"57399_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature05098","volume":"443","author":"JA D\u2019Orazio","year":"2006","unstructured":"D\u2019Orazio, J. A. et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 443, 340\u2013344. https:\/\/doi.org\/10.1038\/nature05098 (2006).","journal-title":"Nature"},{"key":"57399_CR21","doi-asserted-by":"publisher","first-page":"27589","DOI":"10.1038\/srep27589","volume":"6","author":"Y Qiao","year":"2016","unstructured":"Qiao, Y. et al. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Sci. Rep. 6, 27589. https:\/\/doi.org\/10.1038\/srep27589 (2016).","journal-title":"Sci. Rep."},{"key":"57399_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3389\/fphar.2018.01535","volume":"9","author":"C Spana","year":"2018","unstructured":"Spana, C. et al. Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases. Front. Pharmacol. 9, 1535. https:\/\/doi.org\/10.3389\/fphar.2018.01535 (2018).","journal-title":"Front. Pharmacol."},{"key":"57399_CR23","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1021\/jm025539h","volume":"45","author":"IK Sebhat","year":"2002","unstructured":"Sebhat, I. K. et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J. Med. Chem. 45, 4589\u20134593. https:\/\/doi.org\/10.1021\/jm025539h (2002).","journal-title":"J. Med. Chem."},{"key":"57399_CR24","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.peptides.2009.07.012","volume":"30","author":"KG Kumar","year":"2009","unstructured":"Kumar, K. G. et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL\/6J mice. Peptides 30, 1892\u20131900. https:\/\/doi.org\/10.1016\/j.peptides.2009.07.012 (2009).","journal-title":"Peptides"},{"key":"57399_CR25","doi-asserted-by":"publisher","first-page":"e1000993","DOI":"10.1371\/journal.pgen.1000993","volume":"6","author":"N Eriksson","year":"2010","unstructured":"Eriksson, N. et al. Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 6, e1000993. https:\/\/doi.org\/10.1371\/journal.pgen.1000993 (2010).","journal-title":"PLoS Genet."},{"key":"57399_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/509","volume":"19","author":"H Krude","year":"1998","unstructured":"Krude, H. et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet. 19, 155\u2013157. https:\/\/doi.org\/10.1038\/509 (1998).","journal-title":"Nat. Genet."},{"key":"57399_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41594-021-00675-6","volume":"28","author":"AJ Kooistra","year":"2021","unstructured":"Kooistra, A. J., Munk, C., Hauser, A. S. & Gloriam, D. E. An online GPCR structure analysis platform. Nat. Struct. Mol. Biol. 28, 875\u2013878. https:\/\/doi.org\/10.1038\/s41594-021-00675-6 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"57399_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100. https:\/\/doi.org\/10.1038\/s41586-023-06045-0 (2024).","journal-title":"Nature"},{"key":"57399_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0301-4738.37595","volume":"56","author":"R Parikh","year":"2008","unstructured":"Parikh, R., Mathai, A., Parikh, S., Chandra Sekhar, G. & Thomas, R. Understanding and using sensitivity, specificity and predictive values. Indian J. Ophthalmol. 56, 45\u201350. https:\/\/doi.org\/10.4103\/0301-4738.37595 (2008).","journal-title":"Indian J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57399-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:03:34Z","timestamp":1787745814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57399-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57399"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57399-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: T.M.M has received research funding and conducted consultancy for SynAct Pharma ApS. T.E.N.J. is shareholder in SynAct Pharma ApS and owns intellectual property on AP1189. M.P is, advisory board member for SynAct Pharma ApS, and has received research funding from SynAct Pharma ApS. N.K. and C.S.A.D.W declare no conflict of interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26756"}}